Sabby Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Sabby Management’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,260	Closed	-$32K	–	130
2020 Q1	$32K	Buy	+1,260	New	+$53.5K	0.01%	77
2019 Q4	–	Sell	-2,619	Closed	-$127K	–	96
2019 Q3	$129K	Buy	+2,619	New	+$188K	0.07%	74
2017 Q4	–	Sell	-1,434	Closed	-$524K	–	193
2017 Q3	$524K	Buy	+1,434	New	+$509K	0.03%	98
2014 Q2	–	Sell	-868	Closed	-$386K	–	293
2014 Q1	$386K	Sell	868 -4,947	-85%	-$2.24M	0.02%	187
2013 Q4	$2.6M	Buy	+5,815	New	+$2.55M	0.17%	70

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sabby Management's DMK Position: Q2 2020 in Review

Sabby Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2020, closing a stake of 1,260 shares — an estimated $32K sold.

Sabby Management first reported a position in DMK in Q4 2013 and held it in 5 quarters. The position peaked at $2.6M in Q4 2013. 47 funds tracked by Wall St. Rank hold DMK as of Q2 2020.

Sabby Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2020 after selling out during the quarter.
Sabby Management sold 1,260 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2020, an estimated $32K.
Sabby Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 5 quarters.
Sabby Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $2.6M in Q4 2013.
47 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.